Which country does Hui Ling Pharmaceutical come from?

Hui Ling Group was founded by Dr. Frederik Paulsen on 1950. It is one of the earliest companies in the world to produce synthetic peptides, and develops various innovative drugs in different therapeutic fields, including urology, reproductive medicine, obstetrics and gynecology, gastrointestinal tract and endocrine system diseases. Headquartered in Switzerland, Hui Ling Group has factories in Sweden, Denmark, Germany and Czech Republic.

R&D Center is located in the United Kingdom and the United States, with branches in more than 40 countries around the world. In the past 20 years, Hui Ling Group has maintained an annual growth rate of about 20%. In the early 1990s, Hui Ling Pharmaceutical Co., Ltd. established its Asia-Pacific headquarters in Hongkong. In the past ten years, the product has been successfully introduced into many major markets in Asia, enabling more patients to obtain new and appropriate drug treatments.

The development of Hui Ling Pharmaceutical in China;

199565438+On February 27th, Hui Ling Pharmaceutical Co., Ltd. was established in Zhongshan City, Guangdong Province. The company's main business scope is the production and operation of tablets, granules, enemas, oral liquids, small-volume injections, freeze-dried powder injections and imported drug packaging. At present, the enterprise is in the state of opening. Hui Ling Pharmaceutical has been committed to research and development and production of high-quality drugs.

In the past twenty years, the company has established a good reputation in China market, and continuously expanded its business scope to provide services for more patients. As a pharmaceutical enterprise, Hui Ling Pharmaceutical Co., Ltd. has rich experience and technical accumulation in drug production and research and development. The company always follows strict quality control standards to ensure compliance with national standards and customer needs.

Please refer to Baidu Encyclopedia-Hui Ling Pharmaceutical for the above contents.